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ABSTRACT
Mitochondrial mutations, an important cause of
incurable human neuromuscular diseases, are
mostly heteroplasmic: mutated mitochondrial DNA
is present in cells simultaneously with wild-type
genomes, the pathogenic threshold being generally
>70% of mutant mtDNA. We studied whether
heteroplasmy level could be decreased by specific-
ally designed oligoribonucleotides, targeted into
mitochondria by the pathway delivering RNA
molecules in vivo. Using mitochondrially imported
RNAs as vectors, we demonstrated that oligoribo-
nucleotides complementary to mutant mtDNA
region can specifically reduce the proportion of
mtDNA bearing a large deletion associated with
the Kearns Sayre Syndrome in cultured transmito-
chondrial cybrid cells. These findings may be
relevant to developing of a new tool for therapy of
mtDNA associated diseases.
INTRODUCTION
Mitochondria are responsible for many cellular processes
ranging from respiration to apoptosis, and their dysfunc-
tions have severe consequences. Mammalian mitochon-
drial DNA (mtDNA) is a closed circular molecule of
16.5 kb, encoding 13 core proteins that contribute to
oxidative phosphorylation, 2 ribosomal RNAs (rRNAs)
and 22 transfer RNAs (tRNAs) needed for the biosynthe-
sis of these 13 peptides in the mitochondrial matrix
(Figure 1A). More than 200 human neuromuscular incur-
able diseases were associated with mtDNA mutations (1).
One of the striking particularities of the majority of these
pathologies is the simultaneous presence of mutant and
wild-type (WT) mitochondrial genomes in the same cell,
the heteroplasmy (2). Two approaches were proposed to
address mtDNA-associated pathologies by gene therapy.
In some cases, defects may be rescued by targeting into
mitochondria nuclear DNA-expressed counterparts of the
affected molecules, approach called ‘allotopic’ strategy
(3–7). Reducing the level of heteroplasmy, ‘antigenomic’
strategy, is another possibility. To this last goal, several
approaches were tested. One example is mitochondrial tar-
geting of restriction endonucleases cleaving mutated
mtDNA molecules (8–10). Another one was to speciﬁcally
design synthetic peptide nucleic acids (PNA) molecules
inhibiting mutant mtDNA replication. They revealed to
be efﬁcient in vitro but not able to cross the inner mito-
chondrial membrane and, as a result, not capable of inter-
acting with mtDNA in vivo (11–14).
We have exploited RNA mitochondrial import pathway
to target into human mitochondria RNAs able to hybrid-
ize with the mutated mtDNA and to inhibit selectively its
replication. Import of nuclear DNA-encoded RNAs into
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mitochondria is a widely spread phenomenon; however,
the types, number of imported RNAs and targeting mech-
anisms vary among species (15–17). Mammalian mito-
chondria were reported to import several types of small
non-coding RNAs (18), including several microRNAs
(19–21), some tRNAs (in natural or artiﬁcial manner)
(22,23), RNA components of RNase P and MRP endo-
nuclease (24,25) and 5S rRNA (26–28). Recently, we
demonstrated that 5S rRNA import mechanism can rely
on protein import factors identiﬁed as the mitochondrial
enzyme rhodanese and the precursor of mitochondrial
ribosomal protein MRP-L18 (29,30), interacting
with two structural motifs of the 5S rRNA molecule
(Figure 1B), whereas the third motif, so called
b-domain, may be either deleted or replaced without loss
of import capacity (31). Additionally, analysis of artiﬁcial
import of yeast tRNAs derivatives into human
mitochondria (26) permitted us to design short synthetic
RNAs (referred to as FD-RNA) comprising two domains
of the tRNA (Figure 1C) and characterized by a high ef-
ﬁciency of mitochondrial import (32). Here, we show that
these two types of molecules can serve as vectors to deliver
into mitochondria oligoribonucleotides with a therapeutic
potential.
MATERIALS AND METHODS
Clinical case
Patient T was diagnosed with a Kearns Sayre Shy
syndrome at the age of 15 years. He was the second
child of non-consanguinous parents and had a healthy
brother. He ﬁrst came to medical attention at the age of
9 years for progressive left ptosis, ophthalmoplegia, mild
deafness and walking difﬁculties. He was hospitalized at
the age of 15 years. Physical examination disclosed mild
ataxia and muscle weakness with amyotrophy. Brain
imaging showed white matter hypersignals. Biological
analyses showed high CK at 10 times normal values,
high protein (2.65 g/l) and lactate (5.6mM) levels in CSF
and high lactate (2.7mM) in blood. Histological examin-
ation of deltoid muscle biopsy showed numerous ﬁbers
Figure 1. KSS deletion in human mtDNA and anti-genomic RNAs design. (A) Genetic maps of wild-type and mutant KSS mtDNAs. Target
sequence, the sequence of deletion boundaries is shown in red. (B) Secondary structure of human 5S rRNA and its functional elements. Below,
secondary structures of recombinant 5S rRNA b-domains (inserts in red). The arrows show the deletion point. (C) The structures of yeast tRNALys,
short synthetic FD-RNA and two recombinant RNAs containing inserts corresponding to L- and H-strands of KSS-mtDNA (in red). Two domains
derived from the tRNA (32) are shown in pink and blue. The arrows show the deletion boundaries point.
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with important mitochondrial proliferation (‘ragged red
ﬁbres’) and completely defective cytochrome c oxidase
histochemical reaction. Spectrophotometric assays of
muscle mitochondrial activities showed high values of
both citrate synthase and succinate dehydrogenase
activities (above the 95th centile of normal values) reﬂect-
ing the muscle mitochondrial proliferation as well as low
values (below or at the 5th centile of normal values) for
cytochrome c oxidase (complex IV) activity and for the
ratios of complex I, III, or IV activity to either citrate
synthase or complex II. Southern blot analysis of total
DNA from muscle showed the presence of a large size
deletion involving 72% of the mtDNA molecules. Direct
sequencing of the patient’s mtDNA showed that the
deletion spanned from nucleotide 8363 to 15 438,
thus removing 7075 base pairs including 9 structural
genes (MT-ATP8, MT-ATP6, MT-CO3, MT-ND3, MT-
ND4L, MT-ND4, MT-ND5, MT-ND6 and part of MT-
CYB) and 6 tRNA genes (MT-TG, MT-TR, MT-TH,
MT-TS2, MT-TL2 and MT-TE).
Transmitochondrial cybrid cell line construction
Cultured skin ﬁbroblasts were derived from the patient’s
skin biopsy according to routine procedure. After their
ﬁrst passage, they were enucleated and fused to a human
rho0 osteosarcoma cell line (143B) kindly provided by
Prof. E. Shoubridge, Montreal Institute of Neurology,
and cloned by limit dilution as reported (33). Of more
than 80 screened clones, only two had the mtDNA
deletion, involving 65% mtDNA molecules in one case
and 20% in the second case. Cybrid cells containing
65%mutant mtDNA used in this study were characterized
by the 10%±2% decrease of oxygen consumption
comparing to control 143B cell line.
Plasmids and recombinant RNAs
For replication in vitro, two human mtDNA fragments
were cloned in pUC119, 430 bp fragment (nucleotides
15 251–15 680 of mtDNA) referred to as WT-DNA
and 512 bp fragment (nucleotides 8099–8365/15 438–
15 680 of mutant mtDNA) comprising the fusion of the
two boundaries of the Kearns Sayre Syndrome (KSS)
deletion, referred to as KSS-DNA. Cloning was per-
formed by polymerase chain reaction (PCR) with
primers listed in the Supplementary Table S1. For the
real-time PCR calibration curves, two plasmids containing
the 12S rRNA region not touched by the KSS deletion
(nucleotides 109–1714 of mtDNA) and the deleted
region (nucleotides 10 739–11 839 of mtDNA) were con-
structed using pUC119 vector.
All recombinant 5S rRNA versions’ genes were cloned
into pUC119 as described (31). Recombinant RNAs were
obtained by T7 transcription using the T7 RiboMAX
Express Large Scale RNA Production System (Promega)
on the plasmid DNA or the corresponding PCR products.
For synthesis of ﬂuorescently labeled RNA transcript,
Alexa Fluor 488-5-UTP (Molecular Probes) was incor-
porated in RNA during 2 h T7-transcription by T7-RNA
polymerase (Promega). Reaction mixture of total volume
20 ml contained 0.5mg of DNA template, 80 u of T7-RNA
polymerase (2 additions of 40 u each), 0.5mM of ATP,
0.5mM CTP, 0.5mM GTP, 0.37mM UTP, 0.125mM
Alexa Fluor 488-5-UTP, 10mM DTT and 40 u of
RNaseOUT (Invitrogen). T7-transcript was puriﬁed by
PAGE. To check the incorporation of the label in
puriﬁed transcript, we compared the dye absorbance at
492 nm with the absorbance at 260 nm using NanoDrop
Microarray Program. The efﬁciency of labeling obtained
was approximately ﬁve labeled UTP per one RNA
molecule.
For in vivo expression, 5S rRNA gene versions were
PCR cloned either in pBK-CMV phagemid vector
(Stratagene) or in pcDNA3neo/zeo vector (Invitrogen),
as described (31).
Mitochondria isolation
Mitochondria from beef liver were isolated as described in
(26,34). Mitochondria from cultured HepG2 or cybrid
human cells were isolated as described in (34) by several
rounds of high (20 000g) and low (4000g) centrifugations.
After the second round of high-speed centrifugation of
mitochondria, they were re-suspended in the buffer
[0.44M mannitol, 20mM Tris–HCl (pH 7.0), 20mM
NaCl and 1mM EDTA] and centrifuged through two
layers of sucrose (0.5M and 1.5M). Mitochondria were
collected on the top of the 1.5M layer and harvested by
high-speed centrifugation. The integrity of mitochondria
was checked by a citrate synthase assay (35).
In vitro import
To isolate proteins directing import in vitro (IDP), HepG2
cells were harvested in phosphate-buffered saline (PBS)
containing 1mM EDTA, washed with PBS, suspended
in NPMD buffer [20 mM Na-Phosphate buffer, pH 6.5
(alternatively replaced by Tris–HCl, pH 7.5), 150mM
NaCl, 1mM MgCl2, 5mM DTT] containing the cock-
tail of protease inhibitors (Boehringer-Mannheim) and
disrupted by sonication. Cellular debris was removed
by centrifugation, nucleic acids were removed by
polyethylenimine treatment (36), proteins were pre-
cipitated by ammonium sulfate (80% of saturation) and
dialyzed against the NPMD buffer. Import conditions
were as described in (26,31) with several modiﬁcations.
The standard assay (100ml) contained isolated
mitochondria (100 mg of mitochondrial protein), 3
pmoles of 50-end 32P-labelled RNA and 10 mg of IDPs in
the ‘import buffer’ [0.44M mannitol, 20mM HEPES-
KOH (pH 6.8), 50mM KCl, 2.5mM MgCl2, 1mM
ATP, 5mM DTT, 0.5mM PMSF, 0.1mM DIFP,
0.5mM, phosphoenol pyruvate and 1 unit of pyruvate
kinase]. The import assay was carried out at 30C for
20min (37). After treatment with a mixture of nucleases
(20 u/ml of micrococcal nuclease, 15 mg/ml of RNase A
and 25 u/ml of phosphodiesterase in 2 concentrated
stock), mitoplasts were generated by treatment with
digitonin, at 100 mg per mg of mitochondrial protein.
After incubation for 15min at 25C, mitoplasts were har-
vested by centrifugation and washed twice as described
(38). Mitoplasts were then lysed in 1% SDS, 0.1M
sodium acetate (pH 4.8) and 0.05% diethyl pyrocarbonate
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at 100C, and mtRNA was phenol extracted. RNAs were
analyzed by denaturating gel electrophoresis, and import
was quantiﬁed using PhosphorImager (Typhoon-Trio, GE
Healthcare).
Isolation of protein fraction containing replication
enzymes from beef liver mitochondria
Partial puriﬁcation of mammalian mitochondrial replica-
tion enzymes was performed essentially as described in
(39,40). One gram of mitochondria (mitochondrial
protein) was lysed in 20mM Tris–HCl, pH 8.0, 0.1M
NaCl, 20mM EDTA, 10% Glycerol, 14mM 2-mercap-
toethanol, 1% Triton X-100 (v/v), 1mM PMSF and
0.1mM DIFP for 15min at 4C. After removing debris
(40 000g, 1 h), the supernatant was diluted 1.5 times with
20mM Tris–HCl, pH 8.0, 20mM EDTA, 10% Glycerol,
14mM 2-mercaptoethanol and 1mM PMSF and loaded
on DE52 cellulose column equilibrated with the same
buffer with 70mM NaCl. The main peak eluted at 0.3M
NaCl characterized by maximal activity was used in all
analysis. Activity of the DNA polymerase and/or
primase was checked by assaying 1–2 ml aliquots of the
protein fraction in the presence of single-stranded DNA,
[a-32P]-dCTP and either presence or absence of random
primers (pd(N6) (Promega) in 20mM Tris–HCl, pH 7.5,
20mM MgCl2, 75mM KCl, 0.1mg/ml of BSA, 1mM
2-mercaptoethanol, 100mM of each dATP, dGTP and
dTTP. The assay was performed at 37C for 1 h, the
10% TCA-precipitated material ﬁxed on a membrane
and radioactivity measured in scintillation counter.
Incorporation of [a-32P]-dCTP into nascent DNA was
maximal (0.3 pmoles/mg) in the presence of random
primers and 3-fold decreased in the absence of primers,
indicating that eluted protein fraction contained mito-
chondrial enzymes capable of priming and elongating
nascent DNA molecules.
In vitro replication assay
Double-stranded replication template was prepared by
PCR on the cloned mtDNA fragment, to obtain 430 bp
fragment (nucleotides 15 251–15 680 of mtDNA) referred
to as WT-DNA and 512 bp fragment (nucleotides
8099–8365/15 438–15 680 of mutant mtDNA) referred to
as KSS-DNA. To obtain single-stranded templates, we
used the method described in (11). Mainly, the same
PCRs were performed, but one of the primers was
biotinylated (Supplementary Table S1). The PCR
products were then ﬁxed on Streptavidin-agarose beads
(Fluka), the dsDNA denatured in NaOH (0.1M) and
the non-biotinylated strand was eluted and ethanol
precipitated.
For the replication assay, 100 ng of dsDNA or ssDNA
was mixed in ﬁnal volume of 10 ml with [32P]-50-labeled
speciﬁc primer (designed in the way to generate full-size
replication products of similar size for both WT and KSS
mtDNA fragments) in 10mM Tris–HCl, pH 7.5, 1mM
EDTA (TE), heated to 90C and slowly cooled to 37C.
Then, the mixture was adjusted to 20mM Tris–HCl, pH
7.5, 20mM MgCl2, 75mM KCl, 0.1mg/ml of BSA, 1mM
2-mercaptoethanol, 100 mM of each dNTP and 0.5 ml of
mitochondrial protein fraction was added. The reaction
was carried out in the presence of variable amounts of
recombinant RNAs at 37C for 1 h. Replication was
stopped by addition of 10 ml of 0.2% SDS and 20 ml of
TE-saturated phenol, nucleic acids were ethanol-
precipitated and analyzed by 6.5% denaturing PAGE
followed by phosphor imaging in Typhoon-Trio (GE
Healthcare).
Transient and stable transfection of cybrid cells
Transient transfection with synthetic RNAs was per-
formed as described in (31,41), with minor modiﬁcation:
for 2-cm2 well of 80% conﬂuent cells, we used 0.25 mg
RNA. Transfections were performed with Lipofectamin-
2000 in OptiMEM medium (Invitrogen), as proposed in
the supplier’s protocol. OptiMEM was changed to a
standard DMEM medium the next day after the transfec-
tion. The efﬁciency of transfection was estimated
by ﬂuorescence-activated cell sorting (FACS) analysis of
transfected cells for Alexa Fluor 488 ﬂuorescence 48 h
after transfection (in collaboration with Fanny
Monneaux and Frederic Gros, IBMC, Strasbourg).
Transfection procedure did not lead to detectable
decrease of viability of the cells or to signiﬁcant change
of the overall mtDNA amount, suggesting the absence of
recombinant RNAs toxicity.
For stable transfection, 0.5–1.0 mg of corresponding
linearized plasmid DNA was used for each 10-cm2 well
of 85%-conﬂuent cells. Transfection was performed with
Lipofectamin, as described in the supplier’s protocol.
Selection (200–400mg/ml of G418 for pBK-CMV-cloned
versions and 150–200 mg/ml of Zeocine for pcDNA3-zeo)
was applied after 48 h. Subsequent cloning was performed
by serial dilution method.
RNA stability and mitochondrial import in vivo
Mitochondria were isolated from cybrid cells as described
earlier (31,34), treated with digitonin to generate
mitoplasts (mitochondria devoid of their outer
membrane) and RNase A to get rid of non-speciﬁcally
attached RNA. Such a treatment allows to obtain
mitochondria completely free of cytosolic RNA contam-
ination, including 5.8S rRNA, which can be strongly
attached to the outer mitochondrial membrane upon cell
disruption. However, during the RNase and digitonin
treatment and multiple re-puriﬁcation of organelles by
centrifugation, an important part of mitochondria can
be partially disrupted, and thus mitochondrial RNA can
be partially degraded. In fact, we recover only 20–50% of
intact mtRNA, and this yield varies in different experi-
ments (Supplementary Figure S5B). Total and mitochon-
drial RNA were isolated with TRIZol reagent
(Invitrogen).
Expression and mitochondrial import of recombinant
5S RNAs were detected by one-step reverse transcriptase
(RT)-PCR (Qiagen) with primers listed in Supplementary
Table S1. The PCR products were separated by gel
electrophoresis, visualized by ethidium bromide staining
and quantiﬁed using G-Box software. For quantiﬁcation
of recombinant 5S RNA molecules in cells and
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mitochondria, known amounts (0.5–500 fg) of correspond-
ing T7-transcripts were used as a template for RT-PCR
(Supplementary Figure S8). Linear dependence between
the ﬂuorescence of PCR fragment and the template RNA
amount was obtained in the range from 0.5 to 50 fg RNA
per assay, thus allowing the semi-quantitative estimation of
recombinant 5S RNA molecules presence in cells and
mitochondria.
Stability and mitochondrial import of small artiﬁcial
FD-RNA molecules were analyzed by Northern
hybridization of total and mitochondrial RNA with
32P-labeled oligonucleotide probes against the FD recom-
binant RNA or against control cytosolic and mitochon-
drial RNA (Supplementary Table S1). To compare the
stability of different recombinant RNA, relative
concentration of each RNA in various time period
after transfection was calculated as a ratio between the
speciﬁc probe signal and the signal for cytosolic 5.8S
rRNA probe.
Relative amount of each imported RNA inside
the mitochondria was estimated after quantiﬁcation
by Typhoon-Trio scanner as a ratio between the signal
obtained after hybridization with FD probe and the
signal obtained after hybridization with a probe against
the mitochondrial tRNALeu in the same RNA prepar-
ation, as described previously (31). To compare import
efﬁciencies of different RNA molecules, total level of
each RNA molecules in transfected cells should be taken
into account and normalized. For this, the amount of
imported RNA inside the mitochondria was divided by
the ratios calculated in the same way but in total RNA
preparation, which indicate the total level of recombinant
RNA in the cells.
To quantify the recombinant RNA molecules in the
mitochondrial fraction after transfection, the signal
obtained after mitochondrial RNA hybridization with
speciﬁc probe was compared with the signals correspond-
ing to 10–50 ng of corresponding T7-transcripts loaded on
the same gel. The values were normalized to the amount of
cells used for mitochondria isolation. MtDNA molecules
were quantiﬁed by real-time qPCR (iCycler, MyiQ
TM
Real-Time Detection System, Biorad).
mtDNA heteroplasmy level analysis
To isolate total DNA from transfected cells, the cells were
solubilized in 0.5ml of buffer containing 10mM
Tris–HCl, pH 7.5, 10mM NaCl, 25mM Na-EDTA and
1% SDS, then 10 ml of proteinase K solution (20mg/ml)
was added and the mixture incubated for 2 h at 50C; 50 ml
of 5M NaCl was added and DNA precipitated by
isopropanol.
Heteroplasmy level was analyzed by real-time qPCR
using SYBR Green (iCycler, MyiQ
TM
Real-Time
Detection System, BioRad) with primers listed in the
Supplementary Table S1. Two pairs of primers
were used: 1) amplifying the 210 bp fragment of 12S
rRNA gene region (nucleotides 1095–1305 in mtDNA)
not touched by the KSS deletion as a value showing all
mtDNA molecules, and 2) amplifying the 164 bp fragment
of the deleted region (nucleotides 11 614–11 778) as a value
showing WT mtDNA molecules. All reactions were per-
formed in a 20 ml volume in triplicates. PCR using water
instead of template was used as a negative control. PCR
was performed by initial denaturation at 95C for 10min,
followed by 40 cycles of 30 s at 95C, 30 s at 60C and 30 s
at 72C. Speciﬁcity was veriﬁed by melting curve analysis
and gel electrophoresis. The threshold cycle (Ct) values of
each sample were used in the post-PCR data analysis by
MyiQ
TM
software, if only the standard deviation (SD) of
triplicate samples was less than 0.2. In each experiment,
the absolute amounts of the PCR product were
determined by using in parallel the serial dilutions of
known amounts of linearized plasmid DNA (104–107
copies per sample). The KSS heteroplasmy level was
calculated using the formula: mutant mtDNA/total
mtDNA=1 (WT mtDNA/total mtDNA). To evaluate
mtDNA content upon transfections with recombinant
RNAs, real-time PCR was performed using 12S rRNA
gene speciﬁc probes for mtDNA and Actin gene-speciﬁc
ones for nuclear DNA (for sequences of the primers, see
Supplementary Table S1).
mtDNA isolation and replication intermediate
analysis on 2D native agarose gel
Seven hundred square centimeters of 80%-conﬂuent
TSFR cybrids cells was transfected with 70 mg of FD-H
RNA, and mitochondria and mtDNA were isolated in 4
days after transfection as described in (42) with small
modiﬁcations. Cells were disrupted in hypotonic buffer
[HEPES (pH 7.8) 20mM, KCl 5mM, MgCl2 1.5mM,
DTT 2mM, BSA 1mg/ml and PMSF 1 mM] using a
tight-ﬁtting Dounce homogenizer and immediately mixed
with 2.5MSH buffer [Mannitol 525mM, sucrose
175mM, HEPES (pH 7.8) 20mM, EDTA 5mM, BSA
1mg/ml, DTT 2 mM and PMSF 1 mM]. After several
rounds of centrifugation, mitochondria were treated with
DNase I (Boehringer Mannheim) at 4C for 15min.
DNase I activity was inhibited by addition of 15mM
EDTA, mitochondria were washed two times with
1MSH buffer [Mannitol 210mM, sucrose 70mM,
HEPES (pH 7.8) 20mM, EDTA 2mM, DTT 2 mM and
PMSF 1 mM] and puriﬁed on sucrose gradient as
described (42).
For 2D native agarose gel (2DNAGE), 2 mg of mtDNA
was digested by FastDigest BlpI enzyme following manu-
facturer’s recommendations (Fermentas). Cleavage sites
are referred in the following list (co-ordinates/fragment
length, bp): 788–1093/306; 1094–1248/155; 1249–4533/
3285; 4534–5646/1113; 5647–5699/53 and 5700–787/
11 657 (WT mtDNA) or 4583 (KSS mtDNA). Neutral
2D-AGE was performed by the standard method and
run on 0.5% agarose gel for the ﬁrst dimension and on
1% agarose gel containing 0.5 mg/ml EtBr for the second
dimension, as described (43,44). Blots were hybridized
with radiolabeled PCR fragment (nucleotides 8099–8365/
15 438–15 931 of mutant KSS mtDNA), exposed to
PhosphorImager screen, revealed by Typhoon-Trio (GE
Healthcare) and analyzed by ImageQuantTL software
(GE Healthcare).
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Recombinant RNA modeling
To predict secondary structures of recombinant RNA
molecules and estimate their free energy (dG), the
‘Mfold’ program was used (45,46); 5S rRNA variants
secondary structures were corrected in accordance with
data published (47,48). To estimate melting temperatures
for DNA–DNA and RNA–DNA duplexes, we used
IDT Sci-Tools OligoAnalyser 3.1 software (49). Speciﬁc
hybridization with target mtDNA was tested using
Southern-blot hybridization of WT and KSS double-
stranded replication templates (see earlier), corresponding
plasmids and mtDNA fragments with 32P-labeled recom-
binant RNAs in 1PBS at 37C.
In vivo mitochondrial translation
Analysis of mitochondrial protein synthesis was per-
formed as described previously (22) with minor modiﬁca-
tions. Brieﬂy, 600 103 cells were incubated for 10min in
DMEM w/o methionine (Sigma) in the presence of 100 mg/
ml of emetine to block cytoplasmic translation, followed
by 30min with 200mCi/ml [35S]-methionine (Amersham)
and, ﬁnally, 10min chase in the normal growth medium.
Cells were solubilized in a Laemmli’s buffer, sonicated for
5 s to break cellular DNA, incubated for 10min at 37C
and 100 mg of protein was run on a 10–20% gradient
SDS-PAGE. Protein amounts loaded were before
normalized by anti-tubulin and anti-porin immunoblot-
ting of the same preparations. Visualization and quantiﬁ-
cation were performed using Typhoon-Trio and
ImageQuantTL software (GE Healthcare).
RESULTS
Design of RNA-based mitochondrial vectors
To test the anti-genomic strategy (Figure 2A), we used as a
model mtDNA containing a large deletion (nucleotides
8363–15 438) underlying a case of a frequent mitochon-
drial pathology, the KSS (Figure 1A). The deletion in
mtDNA generates a new sequence at the fusion of the
deletion boundaries, further referred to as KSS-DNA,
which can serve as the target for the anti-genomic
RNAs. To use 5S rRNA and FD-RNA as mitochondrial
vectors, the distal portion of the b-domain of 5S rRNA
(Figure 1B) and the linker part between hairpin domains
in FD-RNA (Figure 1C) were replaced by sequences cor-
responding to either H- or L-strand of KSS-DNA
(referred to as 5S-H and 5S-L or FD-H and FD-L corres-
pondingly). The choice of the insert length was driven by
secondary structure and melting temperature prediction
(Table 1 and Supplementary Figure S1). To avoid forma-
tion of stable alternative structures for FD-RNA-L,
carrying the longest insertion of 22 bases, a C to G
mismatch was introduced (Figure S1), resulting in com-
parable predicted melting temperature for hybrids
between the recombinant RNAs and mutant KSS
mtDNA (Table 1). According to Tm predictions, anneal-
ing of recombinant RNAs to WT mtDNA should be
negligible at 37. To validate the selected versions experi-
mentally, we hybridized labeled recombinant RNAs with
mtDNA fragments under physiological conditions,
demonstrating speciﬁc annealing with the mutant (KSS)
but not with WT mtDNA (Figure 2A and B and
Supplementary Figure S2).
All the recombinant RNAs were tested for their import
into isolated human mitochondria as described in (26). It
was observed that the insertion sequences did not affect
the capacity of RNA molecules to be internalized by
mitochondria (Figure 2B). Mitochondrial targeting of
Figure 2. (A) Scheme of the anti-genomic strategy. (B) Southern hy-
bridization of wild-type or KSS mtDNA fragments with labeled recom-
binant RNAs (FD-L and FD-H) at 37C. (C) In vitro import of the
recombinant RNAs. Autoradiography of isolated from puriﬁed
mitochondria RNA separated in denaturing 10% PAAG is presented;
5S rRNA derived molecules above and FD-RNA derived ones below.
The size of RNA molecules is shown at the right. ‘Input’, 1–5% of
RNA used for each assay, representing 30–150 fmoles of labeled RNA.
Mitochondria (+) corresponds to the import assay, Mitochondria ()
to the mock import assay without mitochondria, used as a control for
non-speciﬁc protein–RNA aggregation. (D) The import efﬁciencies, ex-
pressed in fmoles of protected RNA to 0.1mg of mitochondrial protein,
as described elsewhere (32); n, number of independent experiments;
n=3–6, as detailed upon each graph.
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FD-H RNA revealed to be less important compared to
FD-L and FD RNAs, however, still rather efﬁcient. This
can be explained by a possibility of an alternative second-
ary structure for this RNA, missing the D stem-loop
domain and thus less efﬁcient as an import substrate
(Supplementary Figure S1).
To test whether recombinant RNAs imported into
mitochondria are able to interfere with replication of the
mutant mtDNA, an in vitro replication run-off assay was
ﬁrst established (Supplementary Figure S3), permitting to
replicate both strands of mtDNA PCR-ampliﬁed frag-
ments. Addition of recombinant RNAs containing
KSS-H or KSS-L inserts inhibited replication of KSS-
DNA in a dose-dependent manner. In contrast, the
presence of the recombinant RNAs did not signiﬁcantly
inhibit replication of WT mtDNA, supporting the above
data suggesting that recombinant RNAs can discriminate
KSS-DNA from the WT one (Figure 2B). The
anti-replicative effect of FD-RNAs was more pronounced
than that of 5S-L and 5S-H RNAs and allowed up to 60%
inhibition (Supplementary Figure S3). These values are
comparable with those previously reported for PNA
(11), which indicates that natural RNAs can be as efﬁcient
as synthetic PNAs for the anti-genomic strategy.
Transfection of cybrid cells with anti-replicative RNA
To validate the anti-replicative effect of recombinant
RNAs in vivo, we constructed a transmitochondrial
cybrid cell line containing mitochondria from ﬁbroblasts
of a patient diagnosed with KSS syndrome. Heteroplasmy
level (proportion of mutant KSS mtDNA to all mtDNA
molecules) has been analyzed by real-time PCR with
primers listed in the Supplementary Table S1. The
cybrid cell line obtained was characterized by presence
of 65%±2% of KSS mutation in mtDNA, the level
being stable upon more than 3 months of continuous cul-
tivation. The sequence of deletion boundaries was shown
to be the same in ﬁve independent clones and corres-
ponded to deletion of nucleotides 8363–15 438 in
mtDNA, as was shown by direct sequencing of the
patient’s mtDNA (Figure 1A). However, only a very
weak (10%±2%) decrease of oxygen consumption can
be detected in cybrid cells (not shown). The same situation
was already reported for many other mutations in
mtDNA, where the respiration defects detected in
patients’ muscles and nervous tissues have been promin-
ently decreased and almost not detectable in ﬁbroblasts
and cybrid cells (50,51). On the other hand, the absence
of strong respiration phenotype facilitated the manipula-
tions with the cultured cells and allowed us to use this cell
line as a model to validate the anti-replicative effect of
recombinant RNAs in vivo.
Because the in vitro anti-replicative effect of FD-RNAs
was more pronounced, for the in vivo assay, we performed
the transient transfection of KSS cybrid cells with FD-L
and FD-H RNA. First, the efﬁciency of transfection was
evaluated by FACS using ﬂuorescently labeled FD-H
RNA, and it was shown that >95% of cells were trans-
fected (Supplementary Figure S4). Then, cells were trans-
fected with non-labeled FD-RNAs, and amount of RNA
internalized by cells was evaluated by Northern
hybridization of total cellular RNA comparing with the
signals of the known amounts of T7-transcripts loaded on
the same gel. By this approach, we could estimate that
approximately 15% of RNA added to cells were
internalized and can be detected in full-size form 24 h
after transfection (not shown). We also measured the deg-
radation ratio of recombinant RNA in cybrid cells at dif-
ferent time points spanning a 10-day period after
transfection. Surprisingly, recombinant RNAs were de-
tectable in cybrid cells up to 6 days after transfection,
stability of RNAs FD-H and FD-L being slightly more
prominent than that of RNA FD (Figure 3A).
Relative efﬁciency of RNA mitochondrial import was
analyzed by Northern hybridization of RNA isolated
from puriﬁed RNase-treated mitochondria 48 h after
cybrid cells transfection with various RNAs (Figure 3B).
As a negative control, cells were transfected with a
short artiﬁcial RNA containing no import determinants
(referred to as Control RNA, Figure 3B and
Supplementary Figure S5A and B). Contrary to this
RNA found not to be associated with mitochondrial
fraction, recombinant FD-L and FD-H RNA were even
more efﬁciently imported into mitochondria than
FD-RNA without insert (Figure 3B and Supplementary
Figure S5B). The quantitative discrepancy between in vitro
(Figure 2B) and in vivo import data can be explained by
different RNA folding in cells and, also, by an advantage
of more ﬂexible molecules containing linkers between the
two structured domains interacting with the protein
import factors.
The quantity of recombinant RNAs in the mitochon-
drial fraction 2 days after transfection (estimated by
Northern hybridization comparing to known amounts of
corresponding T7-transcripts used as quantitative refer-
ence) corresponded to a value of 3.2±0.5 104 RNA
molecules per cell. Comparing these values with mtDNA
amount, measured by real-time PCR as 1.0±0.1 103
molecules per cell, we can estimate the RNA:mtDNA
molar ratio in organello as 30:1. This estimation validate
Table 1. Melting temperatures prediction for hybrids between the recombinant RNAs and mutant or wild-type mtDNA regions (SD=1.3C,
‘‘b’’, bases)
RNA Homology with
KSS mtDNA
Tm for
KSS mtDNA
Homology with
wt mtDNA
(50-deletion boundary)
Tm for 5
0-deletion
boundary
Homology with wt mtDNA
(30-deletion boundary)
Tm for
30-deletion
boundary
5S-H 15 b 52.1C 8 b 18.2C 8 b 28.1C
5S-L 14 b 45.2C 7 b 16.1C 8 b 16.6C
FD-H 15 b 52.1C 9 b 24.2C 7 b 21.9C
FD-L 21 b (1 mismatch) 51.4C 12 b 34.4C 10 b (1 mismatch) 27.7C
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Figure 3. The effect of recombinant RNA mitochondrial targeting on heteroplasmy level in KSS cybrid cells. (A) Recombinant RNA stability in
transiently transfected KSS cybrid cells. At the left, an example of Northern hybridization of total RNA isolated in different time after transfection
(indicated below) with probes against FD-RNAs used for transfection (FD, FD-L or FD-H) and against 5.8S rRNA to quantify the level of
recombinant RNA in the cells. At the right, time dependence of RNA decay, SD is calculated from at least four independent experiments.
(B) Mitochondrial import of recombinant FD-RNAs in transiently transfected cybrid cells. Northern hybridizations of RNA extracted from cells
or puriﬁed mitochondria 48 h after transfection. Above, RNAs used for transfection are indicated; control is an artiﬁcial RNA not imported into
mitochondria (Supplementary Figure S5A). Relative efﬁciencies of mitochondrial import are shown below, import of FD-RNA is taken as 1
(±SD=0.1, results of one from three independent experiments are presented). (C) Time dependence of KSS heteroplasmy level upon transient
transfection of cybrid cells with various RNA (indicated at the right); KSS, mock-transfected cybrid cells. SD is calculated from three independent
experiments.
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our strategy, because the same order of recombinant RNA
molar excess allowed us to decrease mtDNA replication
in vitro up to 60% (Supplementary Figure S3).
Transient effect of imported RNAs on mutant
mtDNA in vivo
Heteroplasmy levels (percentage of mutant KSS mtDNA
to all mtDNA molecules) were measured in cybrid cells at
different time points spanning a 10-day period after trans-
fection (Figure 3C). We observed a decrease of the pro-
portion of mutant mtDNA by 15–25% in cells transfected
by recombinant RNA containing either KSS-DNA-H or
KSS-DNA-L inserts but not in mock-transfected ones or
cells transfected with FD-RNA (mitochondrially imported
but having no homology to the mt-DNA), indicating that
mitochondrially imported RNA molecules can function as
anti-genomic agents in human cells. Because the effect of
the inserts complementary to both mtDNA strands was
similar, in the next experiment two recombinant
RNA molecules, FD-L and FD-H, were used for trans-
fection simultaneously. Both RNAs were detected in
the mitochondria simultaneously in comparable amounts
(Figure 3B and Supplementary Figure S5B) and provided
the most pronounced decrease of heteroplasmy level by
35%±2% (Figure 3C).
To ascertain the absence of a non-speciﬁc effect on rep-
lication that reduced total mtDNA levels in cells, we
estimated mtDNA amounts in WT and KSS cybrid cells
after transfection with RNAs FD-L and FD-H
(Supplementary Figure S6A). Using real-time PCR, we
compared ratios between mtDNA (gene 12S rRNA) and
nuclear DNA (gene of actin, see Supplementary Table S1).
Variations of this ratio, taken as 1 24 h after transfection,
did not correlate with the heteroplasmy shift. For WT
cells, levels of mtDNA were stable in the range of 10%,
comparable to natural ﬂuctuation values, thus indicating
that no depletion effect has been caused by adventitious
reduction in replication of the WT mtDNA. In KSS
cybrid cells, a slight decrease of 25% from initial
mtDNA level has been observed, probably due to replica-
tion pausing caused by anti-replicative RNAs.
The shift of heteroplasmy in cybrid cells was reprodu-
cibly observed with a 4–6 days delay in respect to the cells
transfection; however, the initial level was consistently
restored within 7–8 days. The temporal character of the
effect could be a consequence of the recombinant RNA
degradation and/or of the novel mtDNA deletion forma-
tion and propagation. The latter suggestion was veriﬁed
by direct sequencing of mtDNA isolated at different time
points after cybrid cells transfection with recombinant
RNAs. No heterogeneity of the deletion boundaries was
found (Supplementary Figure S6B), proving the absence
of other mutant mtDNA molecules that could not be
affected by recombinant RNAs.
Taking into account the degradation ratio of recombin-
ant RNA in the cells (Figure 3A), one can suggest that the
restoration of heteroplasmy level in 7–8 days after trans-
fection coincides perfectly with the time period when
RNA/mtDNA molar ratio should be greatly decreased,
being no more detectable by Northern hybridization.
Thus, one can suggest that the stabilization of the
heteroplasmy shift could be achieved by stable expression
of anti-genomic RNA molecules in the cells.
RNA affects mutant mtDNA replication in vivo
To demonstrate that anti-replicative RNA molecules
affect mutant mtDNA replication in vivo, we used
2DNAGE. This technique separates DNA molecules on
the basis of size and shape, thus permitting to detect
various types of replication intermediate (RI) in speciﬁc
and predictable way (42,52). We compared RIs of mtDNA
isolated from WT and KSS cybrid cells (Figure 4A),
digested with restriction enzyme BlpI, chosen to separate
fragments of different types of mtDNA, as indicated at the
Figure 1A. Because of heteroplasmy, after hybridization
of digested mtDNA with PCR fragment of Cyt b region,
we can see one (for WT mtDNA) or two (for KSS
mtDNA) main spots, corresponding to DNA fragments
of WT and mutant KSS mitochondrial genomes and,
therefore, to two sets of RIs (see cartoon interpretation
on Figure 4B, panel d).
As it was demonstrated previously (53), mtDNA frag-
ments containing the replication origin OH produce two
types of RIs, bubble arc and simple Y arc, their relative
abundance being altered markedly: when larger fragments
of mtDNA were studied, the bubble arc signal increased,
with a concomitant decrease in signal from the Y arc
(illustrated on a scheme above panel d). Analysis of two
DNA fragments on the same gel is a rather unusual situ-
ation for 2DNAGE approach, therefore RIs correspond-
ing to WT mtDNA fragment are not well separated in our
system; however, they correspond perfectly to the pre-
dicted pattern (54). We can detect bubble arc-type RI cor-
responding to WT mtDNA fragment, as well as
slow-moving Y arcs, sensitive to S1 nuclease treatment
(55,56) (Figure 4A and B). The intermediates of mutant
KSS mtDNA replication can be partially masked by WT
mtDNA fragment; however, we detected the descending
part of a Y arc-type RI and a weak bubble arc, visible
upon longer exposition of the blot (not shown).
We compared RIs of mtDNA isolated from KSS cybrid
cells at different periods of time after transfection with
RNA FD-H (Figure 4B, panels a–c) and, as a control,
with a yeast tRNA (tRK1, panels e–g). The patterns of
RIs corresponding to WT mtDNA fragment are rather
similar in post-transfected cells (Figure 4B) indicating
that the replication of WT mtDNA was not signiﬁcantly
altered by recombinant RNA. In contrast, we reprodu-
cibly observed a prominent spot on a small Y
arc-resembling RI corresponding to the mutant mtDNA
fragment 4 days after transfection with RNA FD-H but
not immediately after transfection or 8 days later
(Figure 4B, panel b, see also Supplementary Figure S7
for two other examples of similar experiments). This
kind of spots, caused by a marked increase of RIs
around a speciﬁc point, had been previously described as
mtDNA replication pauses in the sites of speciﬁc protein
binding (43,44), thus allowing us to suggest that the
anti-replicative RNA FD-H enhances replication pausing
at the site of its annealing to mutant mtDNA (Figure 4C).
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The origin of a new RI resembling a small Y arc is still not
clear. We can hypothesize that it might be due to increased
rate of lagging-strand initiation as proposed in (57).
Indeed, a stalled leading H-strand may coincide with the
alternative initiation of an L-strand through strand
switching of the polymerase, resulting in a set of forks
expected to form a Y arc upon 2DNAGE analysis (58).
In non-transfected cells (Figure 4A) or in cells trans-
fected with yeast tRNALys in the same conditions, we
cannot detect any RIs corresponding to replication
pausing (Figure 4B, panels e–g). As mentioned before,
yeast tRNALys is efﬁciently imported into human
mitochondria (Supplementary Figure S5B) but does not
contain any homology to human mtDNA (Figure 1C) and
should not affect its replication. Thus, all our data clearly
demonstrate that the recombinant RNA imported into
mitochondria in vivo leads to a speciﬁc replication pause
of the mutated mtDNA.
Stable effect of imported RNAs on mutant
mtDNA in vivo
Because all our attempts to express FD-RNA in the cybrid
cells in stable manner under the control of external
Figure 4. Recombinant RNA affects mutant mtDNA replication in vivo. (A) The 2DNAGE electrophoresis analysis of mtDNA isolated from
wild-type (WT) and KSS cybrid cells. MtDNA was digested with BlpI, blotted and hybridized with P32 labeled fragment of the Cyt b gene
(Figure 1A). Radio autographs detect DNA fragment of 11 645bp for wild-type mtDNA and two fragments of 11 645 and 4570 bp for heteroplasmic
mtDNA, indicated as WT and KSS on the cartoon at the panel d. (B) The 2DNAGE analysis of mtDNA isolated from KSS cybrid cells in different
periods of time after transfection with RNA FD-H (panels a–c) and as a control with yeast tRNA (tRK1, panels e, f and g) immediately after
transfection (panels a and e), in 4 days (panels b and f) and in 8 days (panels c and g). Panel d, schematic representation of replication intermediates:
in green, replication intermediates corresponding to wild-type mtDNA and in blue, corresponding to mutant mtDNA. b, bubble arcs; Y, y arc; SMY,
slow migrating y arcs. The site of presumptive replication pausing is shown by arrow. (C) Schematic representation of three mtDNA replication
models (see ‘Discussion’ for details and references) and possible effect of anti-replicative recombinant RNA FD-H. OH, OL and OZ, origins of
H-strand, L-strand, and strand-coupled replication, respectively.
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promoters were unsuccessful, we used another set of re-
combinant RNA molecules based on 5S rRNA, one of
which was previously shown to be expressed, correctly
maturated and mitochondrially targeted in human cells
(31). Recombinant 5S rRNA genes (Figure 1B) were
cloned into a phagemid vector in the context optimal for
correct transcript processing, as described previously (31),
and used for a stable transfection of KSS cybrid cells.
Transfectants selected for their resistance to appropriate
antibiotic were cloned. Approximately 20–25 individual
clones of each series—containing the empty vector, WT
or recombinant 5S rRNA genes—were characterized by
similar growth rates, suggesting the absence of toxic
effect of the transgenes expression.
The KSS mutation heteroplasmy level was analyzed in
each clone. Control cell lines (mock-transfection, transfec-
tion with the empty vector or with the vector containing
the WT 5S rRNA gene) generated clones with little vari-
ations of heteroplasmy (Figure 5A), whereas for cells
transfected with 5S-L and 5S-H RNA genes, the occur-
rence of 30% clones with decreased proportion of mutant
mtDNA was observed (Figure 5A). The lower
heteroplasmy levels found in these clones (51–54% for
cells containing 5S-L gene and 37–52% for those contain-
ing 5S-H gene) were then stable during 3 months of con-
tinuous cultivation (Figure 5B and C).
To test the effect of the simultaneous expression of both
5S-L and 5S-H RNAs, the cell line derived from the clone
5S-H2, characterized by the lowest heteroplasmy level
(37%±2%), was transiently transfected with plasmid
containing the 5S-L gene. The resulting cell line, referred
to as 5S-H2+5S-L, was characterized by an additional
shift of the heteroplasmy, from 37%±2% to
30%±2% of mutated mtDNA molecules (Figure 5B).
Expression of both recombinant 5S rRNA molecules in
this cell line was conﬁrmed by RT-PCR analysis with
insert-speciﬁc primers (Supplementary Figure S8A).
Mitochondrial import of recombinant 5S rRNAs was de-
tected in all the clones expressing 5S-L or 5S-H RNA by
RT-PCR with RNA isolated from puriﬁed mitochondria
devoid of cytosolic contaminants (Supplementary
Figure S8B).
The level of recombinant 5S rRNA expression in the
clone 5S-H2 was estimated as 30±5 molecules per cell
using semi-quantitative RT-PCR (Supplementary Figure
S8C). This very low expression is not surprising taking
into account the competition of mutant 5S rRNA with
much more abundant WT 5S rRNA molecules for inter-
action with protein factors of transcription, processing
and export from the nucleus. In the same cell line, 8±2
molecules of recombinant 5S rRNA per cell were found
inside the mitochondria (Supplementary Figure S8C),
indicating the very high efﬁciency of import (25%), as
it was shown previously. This value is certainly
under-estimated, because a signiﬁcant part of mitochon-
drial RNA has been usually degraded during
the mitochondria isolation and puriﬁcation (see Sup-
plementary Figure S5B and ‘Materials and Methods’
section).
Because the respiration phenotype of KSS cells can be
hardly detectable, we used the assay of mitochondrial
protein synthesis to compare WT cells, KSS cybrid cells
and a clone of KSS cells expressing recombinant 5S rRNA
(5S-H2) (Figure 5D and E). Cybrid cells were
characterized by the 25% decrease of total mitochon-
drial translation. As expected, the synthesis of proteins
encoded by the portion of mtDNA deleted in KSS
mutants (Figure 1A) was affected in a more prominent
way, the ratio between Cyt b and Cox1 proteins being
twice lower in cybrid cells comparing to control cell line.
Remarkably, in the clone 5S-H2, the total level of trans-
lation and the Cyt b synthesis were partially restored
(Figure 5D and E). For Cox3 protein, a prominent
decrease in KSS cybrid cells and re-increase in the clone
5S-H2 (Figure 5E) have also been observed.
The results obtained should be considered as a
promising indication on the possibility to obtain
a curative effect on the mitochondrial dysfunction by a
heteroplasmy shift. So far, one cannot exclude that
selected individual clones can have a slightly varying
nuclear background issued from the transfection proced-
ure. To explore this possibility, we analyzed individual
subclones of the 5S-H2 cell lines after prolonged cultiva-
tion and subsequent cloning. As mentioned earlier, this
transgenic line was stable during 3-month-long cultiva-
tion; however, upon additional 6-week cultivation and
subsequent recloning, one among >100 individual
subclones retaining the resistance to G418 was chara-
cterized by a spontaneous loss of 5S-H expression (as
demonstrated by PCR and RT-PCR, Supplementary
Figure S8A and D). This derivant cell line, designed as
5S-H2ko, was analyzed for mitochondrial translation by
pulse-chase assay (Figure 5D and E). It was indeed
observed that the effect of improved mitochondrial trans-
lation found in the original 5S-H2 cell line was lost, and
the ratio of mitochondrially synthesized polypeptides in
5S-H2ko line was nearly identical to that of the initial
KSS cybrid cell line. This result indicates that the
curative effect observed in 5S-H2 line was due to the
presence and, most probably, mitochondrial import of
the recombinant 5S rRNA.
In conclusion, a weak but stable expression and mito-
chondrial import of the recombinant 5S rRNAs in KSS
cybrid cells allowed us to obtain cell lines characterized by
a stable shift of mitochondrial heteroplasmy level
accompanied, for the best expressor, by an improvement
of mitochondrial translation.
DISCUSSION
RNA import pathway as a therapeutic tool
Mutations in mtDNA have been associated with a wide
variety of human disorders (1). Many patients suffering
from mtDNA defects harbor subpopulations of mutated
and WT mtDNA molecules within the same cell and
tissue, a state known as heteroplasmy (14,59). Because
there is no effective treatment for these often devastating
pathologies, one attractive approach would be to
speciﬁcally target mutant mtDNA to prevent it
from replicating, thereby allowing propagation of only
WT genomes. Application of such an ‘anti-genomic,’
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Figure 5. Analysis of clones obtained after stable transfection of KSS cybrid cells with 5S rRNA genes. (A) Heteroplasmy variations in series of
clones of KSS cybrid cells after stable transfection with 5S rRNA genes (indicated at the right). ‘No change,’ number of clones where the
heteroplasmy shifts were comparable to natural ﬂuctuation values (0–5%); ‘low KSS,’ the proportion of KSS mtDNA reduced by >10% and
‘high KSS,’ the proportion of KSS deletion increased by >10%. (B) Stability of the heteroplasmy level in individual clones. Two clones of each series
are presented: KSS, mock-transfected KSS cybrid cells, clones from ‘no change’ set; 5S, cells transfected with the wild-type 5S rRNA gene, clones
from ‘no change’ set are presented; 5S-H and 5S-L, cells transfected with corresponding recombinant 5S RNA genes, clones from ‘low KSS’ series,
see also (C); 5S-H2+5S-L, clone 5S-H2 transfected with 5S-RNA-L gene. (C) Analysis of heteroplasmy levels in individual clones. All clones resulting
from transfection with 5S-L and 5S-R RNAs where the hetroplasmy shift was >10% are presented, number of independent qPCR measurements
n=3. An example of such an assay, demonstrating that the shifts observed were signiﬁcant and cannot be explained by errors of qPCR, is given in
the Supplementary Figure S9. At the right, the summary of heteroplasmy shifts induced by 5S-L and 5S-H RNA is presented. (D) Analysis of
mitochondrial protein synthesis in wild type, KSS cybrid cells, a clone of KSS cells expressing recombinant 5S rRNA (5S-H2) and the derivant of the
same cell line after the loss of recombinant 5S rRNA expression (5S-H2ko), as indicated above the panel. Autoradiography of SDS-PAGE is
demonstrated, products of mitochondrial translation are indicated at the left. @ tubulin and @ porin, immunoblotting of the same preparations,
using as a loading control. The lower panel represents Ponceau S staining of the corresponding membrane. (E) The graphs represent the total level of
mitochondrial translation (normalized to the amount of mitochondrial porin) and the ratio of signals corresponding to individual proteins. Cytb and
Cox3, cytochrome b and subunit 3 of cytochrome oxidase, proteins encoded by the portion of mtDNA deleted in KSS mutants; CoxI and Nd2,
subunit 1 of Cytochrom oxidaze and subunit 2 of NADH-dehyrogenase complexes, the both proteins encoded by the mtDNA region not touched by
the KSS deletion.
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or ‘anti-replicative’, strategy is confronted to two main
problems: facilitating the translocation of the anti-
genomic oligomers through the double mitochondrial
membrane and allowing their access and speciﬁc binding
to mutated region of mtDNA. To resolve the ﬁrst
problem, the natural pathway of RNA import into yeast
and human mitochondria can be useful. Our recent studies
permitted to identify the import determinants in tRNA
and 5S rRNA structures, and a set of small RNA mol-
ecules with signiﬁcantly improved efﬁciency of import into
human mitochondria was designed on this basis (31,32).
In this study, to create a vector system able to target
‘therapeutic’ oligonucleotides into deﬁcient human
mitochondria, we inserted into these RNAs short (14–21
bases) sequences corresponding to the boundaries of a
large deletion in mtDNA associated with a neuromuscular
syndrome KSS. All the recombinant RNAs so obtained
were proven to retain their capacity to be internalized
by human mitochondria in vitro (in isolated human
mitochondria) and in vivo (in cultured cybrid cells).
These data indicate that the pathway of RNA import
into mitochondria can serve for targeting anti-replicative
oligoribonucleotides into mitochondrial matrix.
The second problem consists in speciﬁc binding of the
anti-replicative oligonucleotides to mutated region of
mtDNA. In a previously published study (11,60), synthetic
PNAs were used to increase, comparing to oligodeoxynu-
cleotides, the selective and stable binding to the region of
mtDNA around the mutation site. However, RNA–DNA
duplexes are considered to be, in general, more stable that
DNA–DNA ones (49), so the stretch of ribonucleotides
could target the mtDNA duplex, especially in the region
of the replication machinery progression, where it is
already at least partially destroyed by the helicases. Our
in vitro replication assay showed that, indeed, speciﬁc
oligoribonucleotides interfere with mtDNA replication,
reducing it to the level comparable with that described
for PNA. Therefore, RNA molecules having an important
advantage as natural mitochondrial import substrates
were also suitable for selective inhibition of mutant
mtDNA replication in vitro.
Anti-replicative RNA action in vivo
The mechanism of human mtDNA replication is still a
subject of intense debate (61–63). The idea of
anti-replicative heteroplasmy shift as a therapeutic
strategy (11) was initially based on the strand-displacement
mtDNA replication model that suggested the existence
long single-stranded RIs (64). According to this model,
leading-strand (H, heavy strand) synthesis starts at a
ﬁxed point (OH) and advances approximately two-thirds
of the way around the molecule before second-strand
(L, light strand) synthesis is initiated (Figure 4C). More
recently, another two classes of RIs were described inmam-
malian mitochondria. Detection of RNA–DNA hybrid
intermediates of mtDNA replication gave rise to a model
involving Ribonucleotide Incorporation Throughout the
Lagging Strand (RITOLS) (55,56). This model shares
many features with the strand-displacement one, the main
difference consisting in the presence of displaced H-strand
not in a single-stranded form covered by SSB protein but in
the form of RNA–DNA hybrid, where the lagging strand
RNA may be created by primase or by a nascent RNA
transcript hybridizing with the displaced H-strand in the
30–50 direction (55).
Another type of RIs, DNA–DNA duplexes, especially
predominant in cultured human cells recovering from
mtDNA depletion, has been proposed as compatible
with the products of conventional strand-coupled DNA
synthesis, initiating from sites dispersed across the broad
zone named ori Z (52,53). Alternatively, these DNA–
DNA duplexes could be considered as a consequence of
frequent initiation of lagging-strand DNA synthesis re-
sulting in an increased rate of conversion of RITOLS
RIs to dsDNA ones (57,58).
According to the scheme shown at Figure 4C, for all
the three current models of mtDNA replication,
mitochondrially imported anti-replicative RNA should
cause a replication stalling at the site of RNA annealing
to the mutant mtDNA due to impairing of the replication
fork progression. The similar mechanism has
been proposed to explain the replication forks arrest in
the D-loop region, namely due to the inability of the
replisome helicase to separate regions of short RNA–
DNA hybrid (53). In full agreement with our expectations,
analysis of mtDNA RIs on the 2DNAGE revealed a clear
site of replication pausing detectable only on the fragment
of mutant KSS mtDNA isolated from cells transfected
with recombinant RNA FD-H (Figure 4B). This is a
direct demonstration of recombinant RNA ability to
stall the mutant mtDNA replication in vivo.
Effect of imported RNAs on mtDNA heteroplasmy
To test the anti-replicative RNA efﬁciency in human cells,
the changes of heteroplasmy level in KSS transmito-
chondrial cybrid cells were measured upon the presence
of recombinant RNAs in mitochondria. Two different
strategies were used. First, cells were transiently trans-
fected with small artiﬁcial RNA molecules containing
structural determinants of mitochondrial import and
15–21 bases insertions complementary to the region of
mtDNA around the KSS deletion site. Our data show
that this approach allows targeting a rather high level of
recombinant RNA inside the mitochondria, and this re-
producibly coincides with a shift of KSS mtDNA
heteroplasmy level from 65% to 40–50%, detected
within the 4–6 days period after transfection. This
change of heteroplasmy, if stable, should be enough to
rescue phenotypic defects of oxidative phosphorylation
(59,65). However, the restoration of the initial 65% of
mutant mtDNA in 7–8 days was consistently observed,
most probably being a consequence of the recombinant
RNA degradation, followed by accelerated replication of
shorter mutant mtDNA molecules due to the previously
hypothesized effect of ‘replicative advantage of deleted
mtDNA’ (65,66).
To check whether the permanent presence of recombin-
ant RNA in human cybrid cells would lead to a
more stable effect on the heteroplasmy, another strategy
was used, consisting in a stable expression of 5S
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rRNA-based recombinant RNA genes. This approach
appeared to have also some inconvenient features,
because the expression of recombinant 5S rRNA genes
was relatively weak, detectable by RT-PCR only, which
can be explained by competition with more than 200 nat-
urally present 5S rRNA genes for the transcription and
nuclear export protein factors. A variation in the recom-
binant RNA expression in different clones led to various
effects on the heteroplasmy level—no changes were
detected in 70% of clones, and only in 8 from 25 clones
of each series the shift of KSS mtDNA heteroplasmy level
from 65% to 37–54% was observed. On the other hand,
this strategy provided a heteroplasmy shift stable during
several weeks of cells cultivation, which is a ﬁrst successful
attempt to change the proportion of mutant mtDNA in
living cells by exploiting RNA import.
In our previous study, we have shown that 5S rRNA
molecules with substitution of the helix III and loop C
(Figure 1B) by a heterologic sequence can be imported
into isolated human mitochondria (which was conﬁrmed
also in this study, Figure 2A), but had been imported
in vivo 20 fold more efﬁciently than the WT 5S rRNA,
probably due to the absence of competition between mito-
chondrial import factors and the ribosomal protein L5 for
binding to a mutant 5S rRNA (31). This ﬁnding has been
conﬁrmed in this study, because at least 25% of recom-
binant 5S rRNA internalized by cells has been found in
puriﬁed mitochondrial fraction (Supplementary Figure
S8C). Nevertheless, the amount of stably expressed recom-
binant 5S rRNA was almost 1000-fold lower than in cells
transiently transfected with recombinant FD-RNAs.
Surprisingly, this weak but stable expression of the recom-
binant 5S rRNA was sufﬁcient for a shift of mitochondrial
heteroplasmy level (Figure 5). We can hypothesize that the
persistent presence of even small amounts of
anti-replicative 5S rRNA in mitochondria might have an
effect on the mutant mtDNA comparable with that of
more abundant but rapidly degradable small FD-RNA.
Most part of pathogenic mutations in mtDNA lead to
the manifestation of biochemical and clinical defects only
when a threshold level of heteroplasmy has been reached.
This level may be different not only for different muta-
tions but also for the same mutation in various tissues (2).
Normally, phenotypic effect of mtDNA mutation is much
more prominent in muscles and nervous tissues than in
ﬁbroblasts (50,67). This was exactly the case of KSS
deletion, for which low values (below or at the 5% of
normal) for cytochrome c oxidase (complex IV) activity
and for the ratios of complex I, III or IV activity to either
citrate synthase or complex II in patient’s muscles contain-
ing 72% mutant mtDNA has been shown. However,
cybrid cells containing 65% mutant mtDNA, generated
and used in this study, were characterized by a very low
(10%±2%) decrease of oxygen consumption comparing
to control 143B cell line. Thus, this is not surprising that
the mitochondrial translation was only slightly affected
(25% decrease in KSS cybrids). We can hypothesize that
in cybrid cells, normal mtDNA (which is present in pro-
portion 1:3 to mutant molecules) supports the level of mt
tRNA expression sufﬁcient for almost normal mitochon-
drial translation. Nevertheless, our data show that a stable
shift of heteroplasmy can result in partial restoration of
speciﬁc mitochondrial translation defects found in KSS
cybrid cells (Figure 5E).
Both strategies described here for cultured human cells
can be developed as a potential basis for therapy of mito-
chondrial diseases. Stable expression of 5S-based recom-
binant RNA in cells should be optimized to give more
pronounced effects on the heteroplasmy. Transient trans-
fection approach also appears to be an interesting perspec-
tive, because it represents not genetic but rather
pharmacological intervention, which can give positive
results if the way to stabilize the effect of anti-replicative
agents could be found.
To summarize, we demonstrate here for the ﬁrst time
that the replication of mtDNA containing a known patho-
genic mutation may be speciﬁcally affected by RNA mol-
ecules bearing oligonucleotide stretches complementary to
the mutant region and that these molecules may be
targeted into human mitochondria using artiﬁcially engin-
eered RNA based on 5S rRNA or tRNA as vectors.
Although the inhibitory effect was partial (15–35%
decrease of mutated mtDNA level), it may have a long-
term therapeutic interest, because only high levels of mu-
tations in human mtDNA become pathogenic.
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